cu-64 sartate + cu-67 sartate

Cu-64 SARTATE and Cu-67 SARTATE are copper-based radiopharmaceuticals developed for theranostic use in oncology. Both agents consist of a somatostatin analogue (octreotate) conjugated to the proprietary MeCOSar chelator (SAR Technology), which enables stable binding of copper radioisotopes. Cu-64 SARTATE is primarily used for PET imaging due to its positron-emitting properties, while Cu-67 SARTATE is used for targeted radiotherapy as it emits beta particles. These drugs specifically target somatostatin receptor subtype 2 (SSTR2), which is overexpressed in several tumor types including neuroblastoma and meningioma. The mechanism of action involves binding to SSTR2 on tumor cells, allowing precise imaging or delivery of cytotoxic radiation directly to cancerous tissue. Clarity Pharmaceuticals has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for both agents in neuroblastoma. Clinical trials are ongoing in high-risk pediatric neuroblastoma and meningioma[1][2][4][5][8].

Brand names

SARTATE

Other names

64cu-sar-[tyr3]-octreotate67cu-sar-[tyr3]-octreotate